UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~FORM 8-K

~~Current~~CURRENT ~~Report~~REPORT

Pursuant to Section 13 orOR 15(d)

of The Securities Exchange Act of 1934

Date of Report (~~Date~~date of earliest event reported): ~~June~~ March 11, ~~2024~~2025

MEDICINOVA, INC.

(Exact name of registrant as specified in ~~its~~ charter)

DELAWARE	001-33185	33-0927979
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(I.R.S. EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
4275 EXECUTIVE SQUARE,SUITE 300, LA JOLLA, CA		92037
4275 EXECUTIVE SQUARE,
SUITE 300, LA JOLLA, CA		92037
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 373-1500

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.001 par value MNOV The Nasdaq Stock Market LLC

Common Stock, $0.001 par value

MNOV

The Nasdaq Stock Market LLC

(Title of each class)

(Trading

symbol(s))

(Name of each exchange
on which registered)

~~(Title~~Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of ~~each~~the ~~class)~~Securities ~~(Trading~~Act ~~symbol~~of 1933 (s17 CFR §230.405)) ~~(Name~~or Rule 12b-2 of ~~each~~the ~~exchange~~Securities onExchange ~~which~~Act ~~registered~~of 1934 (17 CFR §240.12b-2).

~~Indicate~~Emerging ~~by check mark whether the registrant is an emerging~~ growth company ~~as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).~~ ☐

~~Emerging~~If an emerging growth company  , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

IfItem an7.01 ~~emerging~~Regulation growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActFD. 

~~Item~~On 5March 11, 2025, MediciNova, Inc.07 ~~Submission~~(the of“Company”) ~~Matters~~updated the slide presentation to abe ~~Vote~~used by the Company at investor meetings. A copy of ~~Security~~the ~~Holders~~revised slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”) and is incorporated herein by reference. The Company does not undertake to update this presentation.

~~MediciNova~~The information in this Report, ~~Inc~~including Exhibit 99.1 ~~(the~~hereto, is being furnished and shall not be deemed “~~Company~~filed”) ~~held~~for ~~its~~the ~~2024~~purposes ~~annual~~of ~~meeting~~Section 18 of ~~stockholders~~the onSecurities ~~June~~Exchange 11Act of 1934, ~~2024~~as ~~(the~~amended (“~~Annual~~Exchange ~~Meeting~~Act”)., ~~The~~or ~~Company~~otherwise ~~filed~~subject ~~its~~to ~~definitive~~the ~~proxy~~liabilities ~~statement~~of ~~for~~that ~~the~~Section, ~~proposals~~and ~~voted~~shall ~~upon~~not atbe ~~the~~deemed ~~Annual~~incorporated ~~Meeting~~by ~~with~~reference in any registration statement or other filing pursuant to the Securities ~~and~~Act ~~Exchange~~of ~~Commission~~1933, onas ~~April 26~~amended, ~~2024~~or (the ~~“Proxy~~Exchange ~~Statement”)~~Act, except as otherwise expressly stated in such filing.

AtItem ~~the close of business on April 17, 2024, the record date of the Annual Meeting, the Company had 49,046,246 shares of common stock issued and outstanding~~9.01 ~~The~~Financial ~~holders~~Statements ~~of a total of 35,566,042 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued~~ and ~~outstanding shares on the record date of the Annual Meeting~~Exhibits.

~~Set~~(d) ~~forth~~Exhibits. ~~below are the results of the matters submitted for a vote of stockholders at the Annual Meeting~~

(1) To elect two Class II Director nominees named below to serve until the 2027 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until his or her earlier death, resignation or removal. The named nominees were so elected, with the votes thereon at the Annual Meeting as follows:


Exhibit No.		Description

99.1		MediciNova, Inc. Presentation

104		Cover Page Interactive Data File (embedded within XBRL document)

~~Final~~SIGNATURES ~~Voting Results~~

Nominees	For	Against	Abstain	Broker Non-Vote
Yuichi Iwaki	24,341,478	7,902,443	886,701	2,435,420
Kazuko Matsuda	24,576,097	7,667,575	886,949	2,435,421

(2) To ratify the selection of BDO USA, P.C. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. This proposal was approved, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

For		Against		Abstain		Broker Non-Vote
27,390,814		7,519,216		654,012		2,000

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDICINOVA, INC.
Date: March 11, 2025		MEDICINOVA, INC.
	~~By:~~	~~/s/ Yuichi Iwaki~~By:	/s/ Yuichi Iwaki
		Yuichi IwakiPresident and Chief Executive Officer
			Yuichi Iwaki
Date: June 12, 2024
			President and Chief Executive Officer

Filing Compare · MEDICINOVA INC